Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 94-104

  He, Song ^a   Lu, Mudan ^a,b   Xue, Wenqun ^b   Wang, You ^a,b   Zhao, Yueming ^a   Gao, Shangfeng ^a   Ke, Qing ^a   Liu, Yonghua ^a   Li, Peng ^a   Cui, Xiaopeng ^a   Cheng, Chun ^a   Shen, Aiguo ^a  

^a NANTONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

HepG2; Human hepatocellular carcinoma (HCC); Ki 67; P p27 Thr157; PI3K Akt; Prognosis; SMMC 7721

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; THREONINE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CDKN1B PROTEIN, HUMAN; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; MUTANT PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; CELL CYCLE; CHEMISTRY; ENZYME IMMUNOASSAY; GENETICS; IN VITRO STUDY; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORPHOLINES; MUTANT PROTEINS; MUTATION; PHOSPHORYLATION; PROGNOSIS; THREONINE; TUMOR CELLS, CULTURED;

EID: 79952251697     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9408-4     Document Type: Article

References (46)

1. EA Akriviadis JM Llovet SC Efremidis D Shouval R Canelo, et al. 1998 Hepatocellular carcinoma Br J Surg 85 1319 1331 9782009 10.1046/j.1365-2168. 1998.00865.x 1:STN:280:DyaK1cvltlaksg%3D%3D (Pubitemid 28468331)
2. J Bruix L Boix M Sala JM Llovet 2004 Focus on hepatocellular carcinoma Cancer Cell 5 215 219 15050913 10.1016/S1535-6108(04)00058-3 1:CAS:528:DC%2BD2cXjtVartbs%3D (Pubitemid 38402113)
3. CJ Sherr JM Roberts 1999 CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 13 1501 1512 10385618 10.1101/gad.13.12.1501 1:CAS:528:DyaK1MXktlOhsLs%3D (Pubitemid 29297917)
4. MA Lawlor DR Alessi 2001 PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114 2903 2910 11686294 1:CAS:528:DC%2BD3MXmvFCqs7c%3D (Pubitemid 32821530)
5. B Vanhaesebroeck DR Alessi 2000 The PI3K-PDK1 connection: more than just a road to PKB Biochem J 346 561 576 10698680 10.1042/0264-6021:3460561 1:CAS:528:DC%2BD3cXit1Kku78%3D (Pubitemid 30171014)
6. J Slingerland M Pagano 2000 Regulation of the cdk inhibitor p27 and its deregulation in cancer J Cell Physiol 183 10 17 10699961 10.1002/(SICI)1097- 4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I 1:CAS:528:DC%2BD3cXhslWqtrw%3D (Pubitemid 30130220)
7. C Catzavelos N Bhattacharya YC Ung JA Wilson L Roncari, et al. 1997 Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer Nat Med 3 227 230 9018244 10.1038/nm0297-227 1:CAS:528:DyaK2sXpsFWisA%3D%3D (Pubitemid 27064710)
8. M Mori K Mimori T Shiraishi S Tanaka H Ueo, et al. 1997 p27 expression, gastric carcinoma Nat Med 3 593 9176477 10.1038/nm0697-593 1:CAS:528: DyaK2sXjsFKksLY%3D (Pubitemid 27264950)
9. M Ciaparrone H Yamamoto Y Yao A Sgambato G Cattoretti, et al. 1998 Localization and expression of p27KIP1 in multistage colorectal carcinogenesis Cancer Res 58 114 122 9426067 1:CAS:528:DyaK1cXitVGltg%3D%3D (Pubitemid 28027726)
10. SP Singh J Lipman H Goldman FH Ellis Jr L Aizenman, et al. 1998 Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma Cancer Res 58 1730 1735 9563491 1:CAS:528:DyaK1cXislerurY%3D (Pubitemid 28215101)
11. G Baldassarre B Belletti P Bruni A Boccia F Trapasso, et al. 1999 Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells J Clin Invest 104 865 874 10510327 10.1172/JCI6443 1:CAS:528:DyaK1MXmsVClsLc%3D (Pubitemid 29536336)
12. V Masciullo A Sgambato C Pacilio B Pucci G Ferrandina, et al. 1999 Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer Cancer Res 59 3790 3794 10446997 1:CAS:528: DyaK1MXltFCns70%3D (Pubitemid 29381888)
13. J Liang J Zubovitz T Petrocelli R Kotchetkov MK Connor, et al. 2002 PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest Nat Med 8 1153 1160 12244302 10.1038/nm761 1:CAS:528:DC%2BD38XnsVGrt7s%3D (Pubitemid 35175971)
14. I Shin FM Yakes F Rojo NY Shin AV Bakin, et al. 2002 PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization Nat Med 8 1145 1152 12244301 10.1038/nm759 1:CAS:528:DC%2BD38XnsVGrt70%3D (Pubitemid 35175970)
15. G Viglietto ML Motti P Bruni RM Melillo A D'Alessio, et al. 2002 Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer Nat Med 8 1136 1144 12244303 10.1038/nm762 1:CAS:528:DC%2BD38XnsVGrt7g%3D (Pubitemid 35175969)
16. N Fujita S Sato K Katayama T Tsuruo 2002 Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization J Biol Chem 277 28706 28713 12042314 10.1074/jbc.M203668200 1:CAS:528:DC%2BD38XmsVGqtbw%3D
17. M Fiorentino A Altimari A D'Errico B Cukor C Barozzi, et al. 2000 Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma Clin Cancer Res 6 3966 3972 11051245 1:CAS:528:DC%2BD3cXotVykurw%3D
18. X Xu H Yamamoto M Sakon M Yasui CY Ngan, et al. 2003 Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas Clin Cancer Res 9 1764 1772 12738732 1:CAS:528:DC%2BD3sXjsFeit7s%3D (Pubitemid 36554602)
19. MV Chakravarthy TW Abraha RJ Schwartz ML Fiorotto FW Booth 2000 Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway J Biol Chem 275 35942 35952 10962000 10.1074/jbc.M005832200 1:CAS:528:DC%2BD3cXosVSktLg%3D
20. G Cattoretti MH Becker G Key M Duchrow J Galle, et al. 1992 Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections J Pathol 168 357 363 1484317 10.1002/path.1711680404 1:CAS:528:DyaK3sXhsVartLc%3D (Pubitemid 23013251)
21. DR Benjamin 1991 Proliferating cell nuclear antigen (PCNA) and pediatric tumors: assessment of proliferative activity Pediatr Pathol 11 507 519 1682901 10.3109/15513819109064787 1:STN:280:DyaK38%2FltFKnsw%3D%3D
22. MM Khine W Aung PD Sibbons CV Howard E Clapham, et al. 1994 Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index Lab Invest 70 125 129 7905542 1:STN:280: DyaK2c7jtlKhtg%3D%3D (Pubitemid 24080112)
23. B Delahunt GJ Farrant PB Bethwaite JN Nacey ME Lewis 1994 Assessment of proliferative activity in Wilms' tumour Anal Cell Pathol 7 127 138 7993823 1:STN:280:DyaK2M%2FosF2rtA%3D%3D (Pubitemid 24278676)
24. K Nakanishi M Sakamoto S Yamasaki S Todo S Hirohashi 2005 Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma Cancer 103 307 312 15593087 10.1002/cncr.20774 1:CAS:528:DC%2BD2MXhtFGlt7Y%3D (Pubitemid 40129290)
25. CJ Vlahos WF Matter KY Hui RF Brown 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J Biol Chem 269 5241 5248 8106507 1:CAS:528:DyaK2cXjtFGit78%3D
26. Kip1 and its potential effect as hepatocellular gene therapy Arch Med Res 39 573 581 18662588 10.1016/j.arcmed.2008.05.002 1:CAS:528:DC%2BD1cXptVWlsLs%3D (Pubitemid 352033609)
27. I Ikai Y Yamaoka Y Yamamoto N Ozaki Y Sakai, et al. 1998 Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy Ann Surg 227 433 439 9527067 10.1097/00000658-199803000-00016 1:STN:280:DyaK1c7os1aqtA%3D%3D (Pubitemid 28131025)
28. ON El-Assal A Yamanoi Y Soda M Yamaguchi M Igarashi, et al. 1998 Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver Hepatology 27 1554 1562 9620326 10.1002/hep.510270613 1:STN:280:DyaK1c3otFKgtA%3D%3D (Pubitemid 28264678)
29. RV Lloyd LA Erickson L Jin E Kulig X Qian, et al. 1999 p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers Am J Pathol 154 313 323 10027389 10.1016/S0002-9440(10)65277-7 1:CAS:528:DyaK1MXjtVCqsb0%3D (Pubitemid 29094081)
30. TF Franke DR Kaplan LC Cantley 1997 PI3K: downstream AKTion blocks apoptosis Cell 88 435 437 9038334 10.1016/S0092-8674(00)81883-8 1:CAS:528:DyaK2sXhtlKqs70%3D (Pubitemid 27154408)
31. A Toker LC Cantley 1997 Signalling through the lipid products of phosphoinositide-3-OH kinase Nature 387 673 676 9192891 10.1038/42648 1:CAS:528:DyaK2sXktVWgt7c%3D (Pubitemid 27270600)
32. A Ullrich J Schlessinger 1990 Signal transduction by receptors with tyrosine kinase activity Cell 61 203 212 2158859 10.1016/0092-8674(90)90801-K 1:CAS:528:DyaK3cXktlKnu74%3D (Pubitemid 20149352)
33. JQ Cheng AK Godwin A Bellacosa T Taguchi TF Franke, et al. 1992 AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas Proc Natl Acad Sci U S A 89 9267 9271 1409633 10.1073/pnas.89.19.9267 1:CAS:528:DyaK3sXks12itbs%3D
34. K Izuishi K Kato T Ogura T Kinoshita H Esumi 2000 Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy Cancer Res 60 6201 6207 11085546 1:CAS:528:DC%2BD3cXotV2ltrw%3D
35. G Kulik JP Carson T Vomastek K Overman BD Gooch, et al. 2001 Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells Cancer Res 61 2713 2719 11289152 1:CAS:528:DC%2BD3MXisVSksb4%3D (Pubitemid 32685859)
36. AA Caro AI Cederbaum 2006 Role of phosphatidylinositol 3-kinase/AKT as a survival pathway against CYP2E1-dependent toxicity J Pharmacol Exp Ther 318 360 372 16624972 10.1124/jpet.106.102921 1:CAS:528:DC%2BD28XmsFymtL0%3D
37. YH Min JW Cheong JY Kim JI Eom ST Lee, et al. 2004 Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia Cancer Res 64 5225 5231 15289327 10.1158/0008-5472.CAN-04- 0174 1:CAS:528:DC%2BD2cXmtF2mtb0%3D (Pubitemid 39006541)
38. A Sgambato A Cittadini B Faraglia IB Weinstein 2000 Multiple functions of p27(Kip1) and its alterations in tumor cells: a review J Cell Physiol 183 18 27 10699962 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S 1:CAS:528:DC%2BD3cXhslWqtr0%3D (Pubitemid 30130221)
39. SW Blain HI Scher C Cordon-Cardo A Koff 2003 p27 as a target for cancer therapeutics Cancer Cell 3 111 115 12620406 10.1016/S1535-6108(03)00026-6 1:CAS:528:DC%2BD3sXhvFyrsr0%3D (Pubitemid 37443384)
40. AL Katner QB Hoang P Gootam E Jaruga Q Ma, et al. 2002 Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1) Prostate 53 77 87 12210483 10.1002/pros.10124 1:CAS:528:DC%2BD38Xns1amtb8%3D (Pubitemid 34966867)
41. G Yang G Ayala A De Marzo W Tian A Frolov, et al. 2002 Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival Clin Cancer Res 8 3419 3426 12429629 1:CAS:528:DC%2BD38XpsVCgt7s%3D (Pubitemid 35340716)
42. M Loda B Cukor SW Tam P Lavin M Fiorentino, et al. 1997 Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Nat Med 3 231 234 9018245 10.1038/nm0297-231 1:CAS:528:DyaK2sXpsFWgsQ%3D%3D (Pubitemid 27064711)
43. Y Jiang RC Zhao CM Verfaillie 2000 Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity Proc Natl Acad Sci U S A 97 10538 10543 10973491 10.1073/pnas.190104497 1:CAS:528:DC%2BD3cXms1Crtrc%3D
44. T Soucek RS Yeung M Hengstschläger 1998 Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2 Proc Natl Acad Sci U S A 95 15653 15658 9861025 10.1073/pnas.95.26.15653 1:CAS:528:DyaK1MXhvFeitw%3D%3D (Pubitemid 29018755)
45. G Orend T Hunter E Ruoslahti 1998 Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells Oncogene 16 2575 2783 9632134 10.1038/sj.onc.1201791 1:CAS:528:DyaK1cXjsFGqsL8%3D
46. G Viglietto ML Motti A Fusco 2002 Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization Cell Cycle 1 394 400 12548012 10.4161/cc.1.6.263 1:CAS:528:DC%2BD3sXitlOktLc%3D